C反应蛋白检测市场－全球产业规模、份额、趋势、机会及预测，依检测类型、检测范围、疾病领域、最终用途产业、地区及竞争状况划分，2020-2030年预测

2024 年全球 C 反应蛋白 (CRP) 检测市场价值为 16.802 亿美元，预计将稳定成长，到 2030 年预计年复合成长率(CAGR) 为 2.10%。 CRP 检测是一种广泛使用的实验室诊断工具，用于测量血液中 C 反应蛋白（一种指示发炎的肝臟产生的生物标记）的浓度。此测试有助于评估身体对感染、损​​伤和慢性病的发炎反应。

医疗保健专业人员经常使用 CRP 测试来诊断和监测多种疾病，包括传染病、自体免疫疾病、心血管疾病和术后併发症。以毫克/公升 (mg/L) 为单位报告的测试结果为发炎的严重程度和进展提供了宝贵的见解，支持及时诊断和疾病管理策略。

关键市场驱动因素

发炎和传染病的盛行率不断上升

主要市场挑战

CRP水平升高缺乏特异性

主要市场趋势

个人化医疗日益受到重视

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：C反应蛋白检测市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依检测类型（免疫比浊法、ELISA、化学发光免疫分析法、其他）
  • 依检测范围（hs-CRP、常规CRP、cCRP）
  • 依疾病领域（心血管疾病、癌症、类风湿性关节炎、发炎性肠道疾病、子宫内膜异位症、红斑性狼疮、其他）
  • 依最终用途行业（医院和诊所、实验室、辅助生活医疗设施、家庭护理、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美C反应蛋白检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲C反应蛋白检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太C反应蛋白检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美洲C反应蛋白检测市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲C反应蛋白检测市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第十三章：全球C反应蛋白检测市场：SWOT分析

第 14 章：竞争格局

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

第 15 章：策略建议

第16章调查会社について・免责事项

Global C-reactive protein (CRP) testing market was valued at USD 1,680.20 million in 2024 and is expected to witness steady growth, with a projected compound annual growth rate (CAGR) of 2.10% through 2030. CRP testing is a widely utilized laboratory diagnostic tool that measures the concentration of C-reactive protein-a liver-produced biomarker indicative of inflammation-in the blood. This test is instrumental in evaluating the body's inflammatory response to infections, injuries, and chronic conditions.

Healthcare professionals frequently use CRP testing to diagnose and monitor a broad range of conditions, including infectious diseases, autoimmune disorders, cardiovascular ailments, and post-surgical complications. Test results, reported in milligrams per liter (mg/L), provide valuable insight into the severity and progression of inflammation, supporting timely diagnosis and disease management strategies.

Key Market Drivers

Increasing Prevalence of Inflammatory and Infectious Diseases

A primary factor fueling market expansion is the growing global burden of inflammatory and infectious diseases. CRP testing is a critical diagnostic and prognostic tool used to detect and monitor a wide spectrum of conditions, including infections, autoimmune diseases, and cardiovascular disorders. As the incidence of these conditions rises globally, the demand for reliable inflammatory biomarkers like CRP continues to grow.

CRP testing is particularly important in managing chronic inflammatory diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and lupus, as well as acute conditions like sepsis and pneumonia. It is estimated that 18 million individuals are affected by RA worldwide, with women comprising 70% of cases and over half of the affected population aged 55 or older. Notably, 13 million people suffer from moderate to severe RA, where early diagnosis and rehabilitation can significantly improve quality of life.

The rising prevalence of autoimmune and inflammatory conditions-driven by a combination of genetic, environmental, and lifestyle factors-has prompted broader adoption of CRP testing in routine clinical diagnostics.

Key Market Challenges

Lack of Specificity in Elevated CRP Levels

One of the key challenges limiting the market's full potential is the non-specific nature of elevated CRP levels. While CRP is a reliable marker of inflammation, it does not provide diagnostic specificity regarding the underlying cause. This ambiguity can complicate clinical decision-making, requiring additional tests to identify the root condition, thereby prolonging diagnosis and treatment initiation.

Furthermore, due to its generalized nature, CRP testing is sometimes ordered inappropriately or excessively, particularly in cases where inflammation may not be clinically significant. This can lead to unnecessary healthcare spending and inefficient utilization of resources, contributing to diagnostic overuse and potential overdiagnosis.

Key Market Trends

Growing Emphasis on Personalized Medicine

The increasing focus on personalized medicine represents a transformative trend shaping the CRP testing market. Personalized medicine seeks to tailor medical treatment based on individual patient profiles, including genetic characteristics, lifestyle, and biomarker data. CRP serves as a critical biomarker for inflammation, enabling healthcare providers to design more targeted and effective treatment plans.

CRP testing plays a pivotal role in risk assessment, particularly for cardiovascular diseases, where elevated CRP levels may signal higher risk and prompt preventive interventions tailored to an individual's needs. It also supports continuous disease monitoring, allowing clinicians to track inflammation over time and make informed adjustments to treatment regimens based on changing CRP values.

Key Market Players

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

Report Scope:

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

C-reactive Protein Testing Market, By Assay Type:

• Immunoturbidimetric Assay
• ELISA
• Chemiluminescence Immunoassay
• Others

C-reactive Protein Testing Market, By Detection Range:

• hs-CRP
• Conventional CRP
• cCRP

C-reactive Protein Testing Market, By Disease Area:

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others

C-reactive Protein Testing Market, By End-User:

• Hospitals & Clinics
• Laboratories
• Assisted Living Healthcare Facilities
• Homecare
• Others

C-reactive Protein Testing Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

Global C-reactive Protein Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. C-reactive Protein Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others)
  • 5.2.2. By Detection Range (hs-CRP, Conventional CRP, cCRP)
  • 5.2.3. By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others)
  • 5.2.4. By End-Use Industry (Hospitals & Clinics, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America C-reactive Protein Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Assay Type
  • 6.2.2. By Detection Range
  • 6.2.3. By Disease Are
  • 6.2.4. By End-Use Industry
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States C-reactive Protein Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Assay Type
      • 6.3.1.2.2. By Detection Range
      • 6.3.1.2.3. By Disease Are
      • 6.3.1.2.4. By End-Use Industry
  • 6.3.2. Canada C-reactive Protein Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Assay Type
      • 6.3.2.2.2. By Detection Range
      • 6.3.2.2.3. By Disease Are
      • 6.3.2.2.4. By End-Use Industry
  • 6.3.3. Mexico C-reactive Protein Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Assay Type
      • 6.3.3.2.2. By Detection Range
      • 6.3.3.2.3. By Disease Are
      • 6.3.3.2.4. By End-Use Industry

7. Europe C-reactive Protein Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Assay Type
  • 7.2.2. By Detection Range
  • 7.2.3. By Disease Are
  • 7.2.4. By End-Use Industry
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany C-reactive Protein Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Assay Type
      • 7.3.1.2.2. By Detection Range
      • 7.3.1.2.3. By Disease Are
      • 7.3.1.2.4. By End-Use Industry
  • 7.3.2. United Kingdom C-reactive Protein Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Assay Type
      • 7.3.2.2.2. By Detection Range
      • 7.3.2.2.3. By Disease Are
      • 7.3.2.2.4. By End-Use Industry
  • 7.3.3. Italy C-reactive Protein Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Assay Type
      • 7.3.3.2.2. By Detection Range
      • 7.3.3.2.3. By Disease Are
      • 7.3.3.2.4. By End-Use Industry
  • 7.3.4. France C-reactive Protein Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Assay Type
      • 7.3.4.2.2. By Detection Range
      • 7.3.4.2.3. By Disease Are
      • 7.3.4.2.4. By End-Use Industry
  • 7.3.5. Spain C-reactive Protein Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Assay Type
      • 7.3.5.2.2. By Detection Range
      • 7.3.5.2.3. By Disease Are
      • 7.3.5.2.4. By End-Use Industry

8. Asia-Pacific C-reactive Protein Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Assay Type
  • 8.2.2. By Detection Range
  • 8.2.3. By Disease Are
  • 8.2.4. By End-Use Industry
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China C-reactive Protein Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Assay Type
      • 8.3.1.2.2. By Detection Range
      • 8.3.1.2.3. By Disease Are
      • 8.3.1.2.4. By End-Use Industry
  • 8.3.2. India C-reactive Protein Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Assay Type
      • 8.3.2.2.2. By Detection Range
      • 8.3.2.2.3. By Disease Are
      • 8.3.2.2.4. By End-Use Industry
  • 8.3.3. Japan C-reactive Protein Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Assay Type
      • 8.3.3.2.2. By Detection Range
      • 8.3.3.2.3. By Disease Are
      • 8.3.3.2.4. By End-Use Industry
  • 8.3.4. South Korea C-reactive Protein Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Assay Type
      • 8.3.4.2.2. By Detection Range
      • 8.3.4.2.3. By Disease Are
      • 8.3.4.2.4. By End-Use Industry
  • 8.3.5. Australia C-reactive Protein Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Assay Type
      • 8.3.5.2.2. By Detection Range
      • 8.3.5.2.3. By Disease Are
      • 8.3.5.2.4. By End-Use Industry

9. South America C-reactive Protein Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Assay Type
  • 9.2.2. By Detection Range
  • 9.2.3. By Disease Are
  • 9.2.4. By End-Use Industry
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil C-reactive Protein Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Assay Type
      • 9.3.1.2.2. By Detection Range
      • 9.3.1.2.3. By Disease Are
      • 9.3.1.2.4. By End-Use Industry
  • 9.3.2. Argentina C-reactive Protein Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Assay Type
      • 9.3.2.2.2. By Detection Range
      • 9.3.2.2.3. By Disease Are
      • 9.3.2.2.4. By End-Use Industry
  • 9.3.3. Colombia C-reactive Protein Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Assay Type
      • 9.3.3.2.2. By Detection Range
      • 9.3.3.2.3. By Disease Are
      • 9.3.3.2.4. By End-Use Industry

10. Middle East and Africa C-reactive Protein Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Assay Type
  • 10.2.2. By Detection Range
  • 10.2.3. By Disease Are
  • 10.2.4. By End-Use Industry
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa C-reactive Protein Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Assay Type
      • 10.3.1.2.2. By Detection Range
      • 10.3.1.2.3. By Disease Are
      • 10.3.1.2.4. By End-Use Industry
  • 10.3.2. Saudi Arabia C-reactive Protein Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Assay Type
      • 10.3.2.2.2. By Detection Range
      • 10.3.2.2.3. By Disease Are
      • 10.3.2.2.4. By End-Use Industry
  • 10.3.3. UAE C-reactive Protein Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Assay Type
      • 10.3.3.2.2. By Detection Range
      • 10.3.3.2.3. By Disease Are
      • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global C-reactive Protein Testing Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Thermo Fisher Scientific, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. F. Hoffmann-La Roche Ltd.
• 14.3. Danaher Corp
• 14.4. Quest Diagnostics
• 14.5. Siemens Healthineers AG
• 14.6. Abbott Laboratories Inc.
• 14.7. Merck KGaAA
• 14.8. Zoetis Inc.
• 14.9. Ortho Clinical Diagnostics
• 14.10.Getein Biotech, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer